Clinical Study
Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson’s Disease
Table 2
PDQ-8, VAS-pain, and CGI-S scores at baseline and after 3 months of months of nightly treatment with rotigotine transdermal patch in the efficacy population ().
| |||||||||||||||||||||||
versus baseline. CGI-S, Clinical Global Impression of Severity; EOT, end of treatment; PDQ-8, short-form Parkinson’s Disease Questionnaire; SD, standard deviation; VAS, visual analogue scale. |